[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematologic-malignancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematologic-malignancy":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,70,0,25,[9,52,112,143,174,202,226,266,288,308,332,360,395,422,441,466,491,518,540,563,583,618,636,665,689],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100516228","phase-1-safety-and-tolerability-of-ziftomenib-combinations-in-patients-with-relapsedrefractory-acute-myeloid-leukemia-100516228",false,"NCT06001788","Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia","Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed\u002FRefractory Acute Myeloid Leukemia","Key Inclusion Criteria:\n\n* Has been diagnosed with relapsed\u002Frefractory AML.\n* Has a documented NPM1 mutation or KMT2A rearrangement.\n* Has a documented FLT3 mutation (cA-3 only).\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2.\n* Has adequate hepatic and renal function as defined per protocol.\n* Has an ejection fraction above a protocol defined limit.\n* Participant, or legally authorized representative, must be able to understand and provide written informed consent prior to the first screening procedure.\n* Has agreed to use contraception as defined per protocol.\n\nKey Exclusion Criteria:\n\n* Has a diagnosis of acute promyelocytic leukemia or blast chronic myeloid leukemia.\n* Has clinically active central nervous system leukemia.\n* Has an active and uncontrolled infection.\n* Has a mean corrected QT interval (QTcF) \\> 480ms.\n* Has uncontrolled intercurrent illness, including, but not limited to protocol defined cardiac disease.\n* Has received radiation, chemotherapy, immunotherapy, or any other anticancer therapy including investigational therapy \\\u003C14 days or within 5 drug half-lives prior to the first dose of study intervention.\n* Has had major surgery within 4 weeks prior to the first dose of study intervention.\n* Has received a hematopoietic stem cell transplant (HSCT) and has not previously had adequate recovery per protocol defined criteria.\n* Has active graft-versus-host disease (GvHD) and or on immunosuppressive drugs for the treatment of GvHD\n* Participant is pregnant or lactating.","ALL","18 Years",{"count":20,"type":21},171,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed\u002Frefractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.",[27,28,29,30,31,32,33,34,35,36,37,38],"AML","AML With Mutated NPM1","Hematologic Malignancy","KMT2Ar","NPM1 Mutation","MLL Rearrangement","Leukemia","Acute Myeloid Leukemia","Leukemia, Myeloid","Leukemia, Myeloid, Acute","Acute Leukemia","Neoplasms by Histologic Type","RECRUITING","2026-08-19",{"date":42,"type":43},"2026-08-20","ACTUAL",{"date":45,"type":43},"2024-02-22",{"date":47,"type":21},"2027-08",{"name":49,"class":50},"Kura Oncology, Inc.","INDUSTRY",45,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":96,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100474891","inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer-100474891","NCT05463796","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer","Inclusion Criteria:\n\n* Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type):\n\n  1-Hereditary risk for cancer including\n  * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes\n  * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)\n  * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)\n  * Hereditary Cancer Prediction Model-based elevated cancer risk\n  * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\\&N cancer for example), etc.\n* Exposed High Risk including\n\n  * Childhood cancer survivors with treatment exposures associated with increased risk of cancer\n  * Adult cancer survivors with treatment exposures associated with increased risk of cancer\n  * Documented high level exposure to group 1 IARC carcinogens\n  * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \\>50, Smoking history of \\>15 pack years, First-degree relative history of lung cancer or COPD\n  * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis\n* Precursor Lesions including\n\n  * Breast: ductal\u002Flobular carcinoma in situ (CIS) and atypical hyperplasia\n  * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia\u002Fadenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis\n  * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia\u002Fcarcinoma in situ,\n  * Lung: Adenomatous hyperplasia\n  * H\\&N: high-risk oral precancerous diseases\n  * Skin: Class II melanocytic lesions. Squamous dysplasia\n  * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas\n  * Thoracic: Lung nodules detected on screening CT that prompt further follow-up\n  * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia\n  * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others.\n* FAMILY MEMBERS or healthy individuals\n\nExclusion Criteria:\n\nThere are no exclusion criteria for the study.\n\nNote: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.",true,{"count":61,"type":21},5000,"20 Years","OBSERVATIONAL","This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.\n\n* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.\n* The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.",[66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,29,86,87,88,89,90,91,92,93,94,95],"Cancer Risk","Cancer Predisposition Syndrome","Hereditary Cancer Prediction","Childhood Cancer Survivors","Adult Cancer Survivors","IARC Carcinogens","Smoking History","Lung Cancer","Ductal\u002FLobular Carcinoma","Barrett Esophagus","Pancreatic Precursor Lesions","Colonic Dysplasia\u002FAdenomata","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Steatohepatitis","Cirrhosis","High Grade Prostatic Epithelial Neoplasia","High-grade Bladder Urothelial Dysplasia\u002FCarcinoma in Situ","Adenomatous Hyperplasia","High-risk Oral Precancerous Diseases","Melanocytic Lesion, Adult","Lung; Node","Serous Tubal Intraepithelial Carcinoma","Endometrial Intraepithelial Neoplasia","Cervical and Endocervical Carcinoma in Situ","Vulvar Intraepithelial Neoplasia","Nephrogenic Rests","Benign Bone Lesions With Risk of Malignant Degeneration","Giant Cell Tumor","Osteochondroma","Spitz Nevus",[97,98,99,100],"Hereditary Risk for Cancer","Childhood cancer survivors","Adult cancer survivors","Precursor Lesions","2026-08-13",{"date":103,"type":43},"2026-08-17",{"date":105,"type":43},"2023-04-25",{"date":107,"type":21},"2031-03-25",{"name":109,"class":110},"Dana-Farber Cancer Institute","OTHER",1,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100416793","phase-1-study-evaluating-the-safety-and-the-efficacy-of-human-t-lymphoid-progenitor-htlp-injection-to-accelerate-immune-reconstitution-after-umbilical-cord-blood-ucb-transplantation-in-adult-patients-with-hematologic-malignancies-htlp-onco-100416793","NCT04707300","Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)","A Phase I\u002FII Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies","HTLP-ONCO","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old and \\\u003C66 years old) at the time of inclusion and eligible for an allogeneic stem cells transplantation and fit to receive the specified conditioning regimen\n* Patients with hematologic malignancies\n* Absence of a matched - related sibling donor (MSD) or a matched unrelated donor (MUD) 10\u002F10\n* Presence of two UCB units with the following criteria\\*: HLA- matched 4\u002F8, 5\u002F8, 6\u002F8, 7\u002F8 or 8\u002F8 for HLA- A, -B, -C and DRB1 loci\n\nAND\n\n• Presence of at least one UCB unit with the following criteria\\*: ≥ 3 x 10e7 TNC\u002Fkg or ≥ 1.5 10e5 CD34+\u002Fkg pre- freezing\n\n\\* For the UCB taken into HTLP culture, the CD34+ content does not need to meet the above cellularity criteria, as expansion during HTLP culture has been proven to ensure the appropriate number of CD7+ needed for each dose.\n\nThe non- cultured UCB will be chosen to have a higher CD34+ cell content in order to enable long- term hematopoietic engraftment\n\n* Absence of Donor Specific Antibodies (DSA) with a MFI \\> 5000\n* Patient affiliated to social security\n* Written, informed consent of the patient\n\nExclusion Criteria:\n\n* Any of the standard contraindications to allogeneic transplant\n* Left ventricular ejection fraction \\\u003C50%\n* Abnormal biochemistry results (ALT\u002FAST\\>10xULN, total bilirubin\\>2.5xULN, creatinin clearance \\\u003C60ml\u002Fmin)\n* Inability to understand and provide informed consent\n* Concomitant infectious disease: HTLV-I, HIV-I or HIV-II\n* Pregnancy or breastfeeding for women of childbearing potential\n* Patients with progressive hematologic malignancies\n* Previous participation within one month before inclusion in another protocol in which drugs may influence immune reconstitution of bone marrow transplantation","66 Years",{"count":122,"type":21},10,[24,124],"PHASE2","This is an open-labelled and non-controlled Phase I\u002FII clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult patients with hematologic malignancies. The dose limiting toxicity of HTLP injection will be evaluated using a model-based design.",[29],[128,129,130,131,132],"acute myeloid leukemia","minimal residual disease","hematologic malignancies","human T Lymphoid Progenitor","umbilical cord blood transplantation","2026-08-10",{"date":135,"type":43},"2026-08-12",{"date":137,"type":43},"2022-02-16",{"date":139,"type":21},"2029-02",{"name":141,"class":110},"Assistance Publique - Hôpitaux de Paris",5,{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":161,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":111},"100507421","feasibility-and-safety-of-collecting-and-combining-autologous-hematopoietic-stem-cells-with-chimeric-antigen-receptor-car-t-cell-therapy-in-subjects-with-relapsedrefractory-hematological-malignancies-100507421","NCT05887167","Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed\u002FRefractory Hematological Malignancies","IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed\u002FRefractory Hematological Malignancies","Inclusion Criteria:\n\n* Age 18 - 85 years.\n* Histologically proven hematological malignancy according to the World Health Organization 2016 classification criteria for which a commercially available, FDA-approved CAR T product exists.\n* Relapsed or refractory disease, defined by the following:\n\n  * Disease progression after last regimen, or\n  * Refractory disease: failure to achieve a partial response (PR) or complete remission (CR) to the last regimen\n* At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy for the malignancy at the time the subject is planned for leukapheresis.\n* Toxicities due to prior therapy must be stable or recovered to ≤ Grade 1 with the exception of alopecia.\n* Subjects with an active uncontrolled infection should not start CAR T treatment until the infection has resolved.\n* Eastern cooperative oncology group (ECOG) performance status 0 - 2.\n* Adequate hematologic, hepatic, and cardiac function\n* Serum pregnancy test for women of childbearing potential (WOCBP) at Screening.\n* Willing to comply to research specimen collection as specified in the protocol.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Autologous hematopoietic cell transplant intent or execution within 8 weeks of planned CAR T infusion.\n* History of allogeneic cell transplantation within 8 weeks of planned CAR T infusion.\n* Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management at time of screening.\n* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment.\n* History of a seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, or any autoimmune disease with CNS involvement.\n* Doses of corticosteroids of greater than or equal to 5 mg\u002Fday of prednisone or equivalent doses of other corticosteroids and other immunosuppressive drugs are not allowed prior to enrollment. A washout period of 10 days prior to leukapheresis and 10 days prior to anti-CD19 CAR T cell administration is required.\n* Any medical condition likely to interfere with assessment of feasibility or safety of study treatment.\n* Live vaccine ≤ 6 weeks prior to planned start of conditioning regimen.\n* History of severe immediate hypersensitivity reaction to any of the agents used in this study.\n* Current pregnancy or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.\n* Subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after the completion of conditioning chemotherapy. Females who have undergone surgical sterilization or who have been postmenopausal for at least 1 year are not considered to be of childbearing potential.\n* In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.\n* Patients with obvious myeloid clonal hematopoiesis on the screening bone marrow biopsy will be excluded based on the risk of developing myeloid neoplasms with aHSC infusion.","85 Years",{"count":152,"type":21},20,[24],"The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed\u002Frefractory (r\u002Fr) hematological disease. The study will evaluate feasibility of collecting the target dose of HSCs from at least 50% of enrolled patients. The study will assess safety based on incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in the first 60 days post CAR T dosing, and also through the collection of adverse events (AEs) and serious adverse events (SAEs) as well as the durability of response after treatment with HSCs with CAR T. The study follows an open-label, single-center and single non-randomized cohort design. 20 subjects with r\u002Fr hematological malignancies will be enrolled and treated to evaluate the feasibility and preliminary safety of collecting autologous HSCs and combining them with CAR T-cell therapy.",[29,156,157,158,159,160],"Large B-cell Lymphoma","Acute Lymphoblastic Leukemia","Mantle Cell Lymphoma","Multiple Myeloma","Diffuse Large B Cell Lymphoma",[162,163,164,165],"CAR T-cell therapy","autologous hematopoietic stem cells","CAR T","CAR T therapy","2026-08-06",{"date":133,"type":43},{"date":169,"type":43},"2024-03-02",{"date":171,"type":21},"2027-12-15",{"name":173,"class":110},"Joshua Sasine, MD, PhD",{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":201},"100589944","mosaic-trial-for-stem-cell-transplant-recipients-100589944","NCT06960993","Mosaic Trial for Stem Cell Transplant Recipients","Mosaic: RCT of a Digital Health Intervention for English- and Spanish-speaking Stem Cell Transplant Recipients","Mosaic","Inclusion Criteria:\n\n* Diagnosed with a hematologic cancer according to medical records\n* Scheduled for or preparing for scheduling of an allogeneic or autologous stem cell transplant at one of our study sites\n* Aged 18 or older (no upper limit)\n* English or Spanish Proficient\n* Interested in using a website to learn about stem cell transplant\n* Ability to understand and willingness to sign an informed consent document and comply with all study procedures\n\nExclusion Criteria:\n\n* Currently participating in a behavioral intervention targeting distress, health-related quality of life, or symptoms\n* Undergoing the first in a planned tandem stem cell transplant\n* Unable to provide meaningful consent (severe cognitive impairment or language difficulties)",{"count":183,"type":21},356,[185],"NA","The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups).\n\nThe main questions this trial aims to answer are:\n\n1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life?\n2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and\u002For reductions in avoidant coping and perceived stress?\n3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English\u002FSpanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.",[29,188,189,33,190,159,191],"Stem Cell Transplant","Bone Marrow Transplant","Lymphoma","Myelodysplastic Syndromes","2026-07-31",{"date":194,"type":43},"2026-08-03",{"date":196,"type":43},"2025-04-28",{"date":198,"type":21},"2030-02-01",{"name":200,"class":110},"Northwestern University",3,{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":111},"100608590","onc-mm-2407-the-effect-of-virtual-reality-headsets-on-pain-and-anxiety-in-the-peri-and-post-bone-marrow-biopsy-period-100608590","NCT07203534","ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period","The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign an IRB-approved informed consent directly.\n2. Must be 18 years or older at time of consent.\n3. Scheduled for an outpatient bone marrow biopsy (BMB) and\u002For bone marrow aspiration (BMA). Note that this does not need to be the participant's first BMB\u002FBMA.\n4. Participant should be suspected of or being diagnosed with a malignant hematologic disease (i.e., Acute or chronic leukemia, lymphoma, clonal plasma cell disorder, etc.) per the investigator.\n5. Ability to read and understand the English language.\n6. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n1. Participant is prescribed analgesics or anxiolytics for the purpose of reducing pain or anxiety prior to the procedure.\n2. Participant with known intolerance to using virtual reality devices, significant motion sickness, history of seizures, history of vestibular disorders, or heart conditions (unstable angina, recent myocardial infarction within the last 3 months, decompensated heart failure, uncontrolled arrhythmias-ventricular tachycardia, a fibrillation with rapid ventricular rate), history of postural orthostatic tachycardia syndrome (POTS) per participant report.\n3. Participants with pacemakers, defibrillators, hearing aid, or other implanted medical device. The Meta Quest device contains magnets and components that emit magnetic\u002Felectromagnetic fields which could affect the operation of nearby electronics and medical devices.\n4. Planned to undergo the bone marrow biopsy\u002Fbone marrow aspiration via Interventional Radiology or as an inpatient admission.",{"count":210,"type":21},160,[185],"The purpose of this research study is to see if a virtual reality (VR) headset is useful in reducing physical discomfort and anxiety experienced by patients who are scheduled to undergo a bone marrow biopsy (BMB) and\u002For bone marrow aspiration (BMA).",[29],[215,216],"Bone Marrow Biopsy","Virtual Reality Headset","2026-07-21",{"date":219,"type":43},"2026-07-23",{"date":221,"type":43},"2026-01-23",{"date":223,"type":21},"2028-02",{"name":225,"class":110},"Wake Forest University Health Sciences",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":248,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100647682","study-to-characterize-mismatched-to-fully-hla-matched-ossium-hpc-marrow-and-living-donor-transplantation-in-patients-with-hematologic-malignancies-100647682","NCT07710781","Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies","A Multicenter, Open Label Study to Evaluate the Efficacy, Tolerability, and Safety of Partially to Fully HLA-Matched Allogeneic Cryopreserved Deceased-Donor Bone Marrow Transplantation and Living Donor Transplantation in Patients With Hematologic Malignancies","Inclusion Criteria:\n\n1. Patient has the ability to provide informed consent according to the applicable regulatory and local institutional requirements.\n2. Male or female, aged ≥12 and ≤65 years for patients receiving MAC aged ≥12 and ≤75 years for patients receiving RIC. Patients between 75 and 80 years on RIC regimen can be enrolled with prior sponsor approval\n3. Patient must require first allogeneic HCT per the discretion of the treating physician\n4. BMI \\\u003C=50 (BMI of 45.1 to 50 maybe allowed after sponsor approval)\n5. For treatment from Ossium product only- no suitable donor available after 3 weeks of search\n6. Patient must be high-resolution:\n\n   1. HLA partially or fully matched (4-8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available Ossium HPC, Marrow product for experimental arm\n   2. HLA fully matched (8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an unrelated available PBSC donor for observational standard of care arm\n   3. HLA partially matched (4-7\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available PBSC donor for observational standard of care arm\n   4. HLA haploidentical matched (4\u002F8 allele matched at HLA-A, -B, -C, DRB1) to available PBSC donor for observational standard of care arm\n   5. HLA partially matched (4-8\u002F8 allele matched at HLA-A, -B, -C, DRB1) to an available living bone marrow donor for optional observational standard of care arm\n7. Stated willingness to comply with all study procedures and availability for the duration of the study\n8. Patient with malignant hematologic disease including:\n\n   1. Diagnosed with acute leukemia \\[acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute biophenotypic leukemia (ABL), or acute undifferentiated leukemia (AUL)\\], , in the first remission or beyond with ≤5% marrow blasts and no circulating blasts or extra-medullary disease documented by bone marrow assessment within 42 days prior to anticipated start of conditioning or\n   2. MDS without Grade 3 fibrosis (Patients with Grade 1 and Grade 2 fibrosis can be enrolled with prior sponsor approval)\n   3. Chronic Lymphocytic Leukemia (CLL) eligible for allogeneic transplant or\n   4. Chronic Myeloid leukemia (CML) eligible for allogeneic transplant\n   5. Chemosensitive lymphomas in the first remission or beyond documented by PET\u002FCT imaging and bone marrow assessment within 42 days prior to anticipated start of conditioning\n   6. Other rare hematological malignancy indications eligible for allogenic transplant will require prior sponsor review and approval\n   7. Absence of active CNS disease due to underlying hematological disease\n9. Karnofsky performance status score ≥70% (MAC) or ≥60% (RIC)\n10. HCT comorbidity index (HCT-CI) ≤5\n11. Adequate organ function defined as:\n\n    1. Cardiac: LVEF at rest ≥40% (RIC) or LVEF at rest ≥45% (MAC)\n    2. Pulmonary: DLCO, FEV1, FVC ≥50% predicted by pulmonary function tests (PFTs). DLCO value may be corrected (dinakara correction) for hemoglobin.\n    3. Hepatic: total bilirubin ≤2.0 mg\u002FdL (except Gilbert syndrome ), and ALT, AST, and ALP \\\u003C3 x upper limit normal (ULN), unless ALT, AST, and\u002For ALP are disease related\n    4. Renal: CrCl\\> 45 mL\u002Fmin\u002F1.73m2 must be obtained (measured by 24-hour urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR (by Cockcroft-Gault formula)) or Cystatin-C test.\n\nExclusion Criteria:\n\n1. Autologous transplant within 6 months\n2. Prior allogeneic HCT\n3. Myeloproliferative disorders or MDS with grade 3 and higher fibrosis are excluded\n4. HTLV-ATLL positive patients are excluded\n5. Currently Pregnant or Currently lactating parent\n6. Participation with an investigational trial within 3 months of planned transplant (Note: participation in survey studies or standard of care studies maybe allowed after sponsors approval or are part of long term follow up for an interventional trial)\n7. Recipient of allogeneic CART-T therapy\n8. Recipient of checkpoint inhibitor in last 3 months\n9. Current uncontrolled bacterial, viral or fungal infection defined as currently taking medication with evidence of progression of clinical symptoms or radiologic findings\n10. Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that in the investigator's opinion precludes participation\n11. Presence of donor-specific antibodies. Recipient has positive anti-donor HLA antibodies against a mismatched HLA in the selected donor determined by either:\n\n    1. positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) or\n    2. presence of donor specific HLA antibodies (DSA) to any mismatched HAS allele\u002Fantigen at any of the following loci (HLA-A, -B, -C, -DRB1, -DPA1, -DPB1) with median fluoresce intensity (MFI) \\>3000 by Luminex single antigen bead based solid phase immunoassay tested prior to SSA request and repeated if transplant is \\>30 days from prior HLA antibody testing or if patient receives additional blood products\u002Ftransfusion prior to transplant\n    3. Patients with donor specific HLA antibodies (DSA) to donor that is reduced post treatment of de-sensitization for DSA","12 Years","75 Years",{"count":236,"type":21},300,[185],"Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.",[29,37,157,34,240,241,242,243,244,245,246,247],"Acute Biphenotypic Leukemia","Acute Undifferentiated Leukemia","CLL (Chronic Lymphocytic Leukemia)","Chronic Myeloid Leukemia","MDS (Myelodysplastic Syndrome)","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Cutaneous T Cell Lymphomas (CTCL)",[33,249,17,27,250,251,189,252,190,253,254,255],"Hematologic Diseases","ABL","AUL","Stem cell Transplant","MDS","CLL","CML","NOT_YET_RECRUITING","2026-07-16",{"date":259,"type":43},"2026-07-20",{"date":261,"type":21},"2026-12-01",{"date":263,"type":21},"2031-03-31",{"name":265,"class":50},"Ossium Health, Inc.",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":279,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":284,"leadSponsor":286,"locationsCount":111},"100612733","phase-1-cd45ra-depleted-cd19-car-t-cell-consolidation-after-tcrcd19-b-cell-depleted-haploidentical-hematopoietic-cell-transplantation-for-relapsedrefractory-cd19-all-and-lymphoma-100612733","NCT07257419","CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+\u002FCD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed\u002FRefractory CD19+ ALL and Lymphoma","Inclusion Criteria:\n\nRecipient\n\n* Age less than or equal to 21 years\n* High risk hematologic malignancy where allogeneic transplantation is the current standard of care. This includes (but is not limited to):\n\n  * High risk CD19+ B cell ALL in CR1 or CR2\n  * Any CD19+ B-cell ALL in CR3 or subsequent\n* If prior CNS leukemia, it must be treated and in CNS CR\n* Left ventricular ejection fraction \\> 40%, or shortening fraction ≥ 25%\n* Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml\u002Fmin\u002F1.73m2\n* Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)\n* Bilirubin ≤ 3 times the upper limit of normal for age\n* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n\nDonor\n\n* At least single haplotype matched (≥ 4 of 8) family member\n* At least 18 years of age\n* HIV negative\n* If sexually active, agreement to use birth control until 2 weeks after completion of the mobilization and apheresis procedure\n* Regarding donation eligibility, is identified as either:\n\n  * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR\n  * Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271\n\nExclusion Criteria:\n\nRecipient\n\n* Has a suitable HLA-identical sibling or suitable 12\u002F12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame\n* Any other active malignancy other than the one for which this HCT is indicated\n* Received a prior allogeneic HCT at any time\n* Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment\n* If sexually active, agreement to use birth control until 6 months after T cell infusion\n* Breast feeding\n* Any severe current uncontrolled bacterial, fungal or viral infection\n\nDonor\n\n* Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female\n* If female, breast feeding","21 Years",{"count":5,"type":21},[24],"The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.\n\nPrimary Objective:\n\n\\- To assess the safety and feasibility of combining CD19-CAR(Mem) T cells after TCRαβ+\u002FCD19 depleted haploidentical donor transplantation for pediatric patients with relapsed\u002Frefractory CD19+ B-cell malignancies.\n\nSecondary Objectives:\n\n* To estimate 1-year post-transplant overall survival, event-free survival, and GVHD-free relapse-free survival (GRFS).\n* To estimate cumulative incidence of engraftment, acute and chronic GVHD, and immune-related adverse events, including CRS and ICANS.",[277,278,29],"Relapsed Pediatric ALL","Hematopoietic Cell Transplantation",[280],"Relapsed\u002FRefractory ALL",{"date":282,"type":43},"2026-07-17",{"date":194,"type":21},{"date":285,"type":21},"2035-12",{"name":287,"class":110},"St. Jude Children's Research Hospital",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":111},"100557027","mindfulness-intervention-for-sleep-disturbance-and-symptom-management-in-hematologic-cancer-patients-during-and-after-inpatient-treatment-100557027","NCT06532773","Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment","Inclusion Criteria:\n\n1. Male and female patients, \\>18 years old\n2. Initial or recurrent diagnosis of acute myeloid leukemia, acute lymphoblastic leukemia, Non-Hodgkin's lymphoma, multiple myeloma, or myelodysplastic syndrome\n3. at least 7 days of hospitalization for treatment (e.g., chemotherapy, CAR-T immunotherapy)\n4. 8 or greater on the Insomnia Severity Index with timeframe adjusted to be \"past 7 days\"\n5. Ability to speak and read English, and intact hearing and vision\n\nExclusion Criteria:\n\n1. Reported or suspected cognitive impairment, confirmed via Folstein Mini-Mental Status Exam \\\u003C25\n2. Serious psychiatric (e.g., schizophrenia, suicidal intent) or medical condition (e.g., seizure disorder, narcolepsy) indicated by medical chart, oncologist, or other provider\n3. Expected survival of \\\u003C6 months",{"count":295,"type":21},60,[185],"People with hematologic cancer often have sleep disturbance and symptoms of fatigue, stress, and pain. This study is being done to test a mindfulness intervention for sleep disturbance and symptom management in patients with hematologic cancer during and after inpatient treatment (Nite2Day+). Participants will complete a baseline survey online, using a mobile application, or paper\u002Fpencil. Once the baseline survey is complete, participants will be randomized (like a flip of a coin) to receive Nite2Day+ or Standard Care. Nite2Day+ will include activities during and after inpatient treatment. During inpatient treatment, participants will use a mobile app to access: 1) mindfulness meditations, 2) brief sleep education videos, and 3) brief videos teaching strategies to improve sleep quality in the hospital. After inpatient treatment, participants will complete 6, videoconference sessions (45-60 minutes) with a trained therapist to learn mindfulness and behavioral coping strategies to self-manage nighttime sleep disturbance and daytime symptoms of fatigue, stress, and pain. Three follow-up surveys will occur at hospital discharge, and approximately 8, and 12 weeks after hospital discharge. Participants randomized to Nite2Day+ will be given the option to complete an exit interview to provide feedback on the Nite2Day+ program. Participants randomized to Standard Care will only complete the four surveys. All participants will continue to receive their usual medical care. The total study duration is about 16 weeks.",[29],"2026-07-07",{"date":301,"type":43},"2026-07-08",{"date":303,"type":43},"2026-01-14",{"date":305,"type":21},"2029-06-30",{"name":307,"class":110},"Duke University",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":12,"sex":17,"minAge":272,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":111},"100592135","implementation-of-an-oral-chemotherapy-adherence-intervention-100592135","NCT06989489","Implementation of an Oral Chemotherapy Adherence Intervention","Design and Implementation of a Social Cognitive Theory-based Medication Adherence Intervention","Inclusion Criteria:\n\n* Adult (age ≥21 years-old) patients\n* Diagnosed with a solid or hematologic malignancy\n* Monotherapy on oral anticancer agent on treatment for at least 6 months\n\nExclusion criteria:\n\n* Patients on time-limited or intermittent therapy (non-continuous)\n* Patients on comfort (end-of-life) care\n* Patients enrolled on hospice",{"count":210,"type":21},[185],"The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural). The study will include 160 adult participants with either solid tumors or hematologic malignancies who have been taking oral anticancer agents for at least six months.\n\nThis study will have two groups of participants, a pre- and post-implementation group. In the pre-implementation of the program group, investigators will administer a survey to the 80 participants and gather information about their medication prior to their enrollment of the program. Similarly, 80 participants who have been enrolled into this program for at least 6 months will serve as the post-implementation group. These patients will be administered the same survey. The results from both groups will be analyzed to see how effective the medication adherence program is.",[319,29],"Solid Tumor",[321,322,323],"oral anticancer agent","oral chemotherapy","adherence","2026-07-06",{"date":301,"type":43},{"date":327,"type":43},"2025-05-28",{"date":329,"type":21},"2028-08-30",{"name":331,"class":110},"UNC Lineberger Comprehensive Cancer Center",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":346,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":359},"100593443","phase-2-a-study-of-belumosudil-in-people-at-risk-of-developing-graft-versus-host-disease-after-a-stem-cell-transplant-100593443","NCT07006506","A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant","Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Patients ≥ 18 years-old at time of consent.\n* Diagnosis: hematologic malignancy in morphologic remission who will be treated with RI or NMA conditioning and GVHD prophylaxis CNI-based (CNI without PTCY) plus abatacept or PTCY-based (CNI with PTCY).\n* Recipients of 7-8\u002F8 related or unrelated HLA-matched or related haploidentical donor.\n* Peripheral blood stem cell graft\n* Allo-HCT day \\\u003C120 at time of consent\n\nPost-HCT inclusion criteria (within 3 weeks before start of belumosudil treatment)\n\n* Patient has received an allo-HCT transplant and is in morphologic remission (blasts \\\u003C5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed.\n* Patient has achieved engraftment. Engraftment is defined as ANC≥500\u002FμL and platelets ≥ 20000\u002FμL on 3 consecutive measurements (each occurring at least 1 day apart). The patient must not have had a platelet transfusion within 7 days before the first measurement.\n* Patient is ≥ 80 days and ≤ 20 days from allo-HCT infusion.\n* Karnofsky score ≥ 70%.\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN)\n* Total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia).\n* Glomerular filtration rate (GFR) ≥ 30 mL\u002Fmin\u002F1.73 m2\n* Female subjects of childbearing potential (≤ 50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months.\n\n  ° Sexually active females of childbearing potential enrolled in the study must agree to consistently use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes: \\* Intrauterine device (IUD) plus one barrier method \\* Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method \\* 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or \\* A vasectomized partner\n* For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* Recipient of CD34+ selected or engineered stem cell graft.\n* Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin).\n* Evidence of current uncontrolled cardiovascular conditions, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.\n* Pulmonary dysfunction with DLCO \\\u003C50% corrected for hemoglobin\n* Patients with an active secondary malignancy or prior malignancy requiring systemic therapy within the past 5 years. Exceptions include adequately treated localized non melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma), as well as localized prostate cancer considered low risk and stable under treatment or surveillance.\n\nPost-HCT exclusion criteria\n\n* Uncontrolled infection, including active hepatitis B and C. Definitive therapy for infection is required and must have no signs of progression within 7 days of the first day of study drug treatment.\n* Use of investigational agent within 14 days pre-HCT or anytime thereafter.\n* Active acute or chronic GVHD requiring systemic therapy (topical or local therapies are allowed).\n* Active treatment with corticosteroids at a dose of ≥ 0.25 mg\u002Fkg\u002Fday for non-GVHD indication.\n* Uncontrolled psychosis, active suicidal ideation, or psychiatric hospitalization within the past year\n* Female patient who is pregnant or breastfeeding.\n* Prior therapy with belumosudil.\n* Known allergy or sensitivity to belumosudil or any other ROCK2 inhibitor.",{"count":340,"type":21},46,[124],"The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.",[344,345,29],"Graft Versus Host Disease","Graft Vs Host Disease",[344,345,29,347,348,188,349,350],"Hematologic malignancy in morphologic remission","Belumosudil","Memorial Sloan Kettering Cancer Center","25-033","2026-06-25",{"date":353,"type":43},"2026-06-29",{"date":355,"type":43},"2025-05-21",{"date":357,"type":21},"2029-05-21",{"name":349,"class":110},8,{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":111},"100616063","comparing-diosmin-hesperidin-and-loratadine-to-prevent-bone-pain-from-g-csf-in-patients-with-blood-cancers-100616063","NCT07300735","Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers","A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies","Inclusion Criteria:\n\n* Adults 18 to 65 years old\n* Receiving a G-CSF for one of the following indications:\n\nTreatment of neutropenia along with treatment for leukemia or lymphoma Neutropenia prevention following autologous hematopoietic cell transplant\n\n* Patients with or without bone pain associated with G-CSF administration.\n* Willingness to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with solid tumors.\n* Pregnant or breastfeeding women.\n* Patients with known allergies or hypersensitivity to Loratadine, Diosmin- Hespiridin or Filgrastim.\n* Patients with pre-existing bone disorders or receiving bone modifying agents\n* Chronic use of antihistamines, Diosmin-Hespiridin, NSAIDs, corticosteroids, or immunosuppressants.\n* Receiving medications with drug interaction grade X with Loratadine, Diosmin-Hespiridin or Filgrastim\n* Patients who are unable to understand or provide informed consent","65 Years",{"count":369,"type":21},88,[185],"This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain.\n\nThe study is comparing two oral medications for their effectiveness as a preventive treatment:\n\n* Diosmin-Hesperidin (a flavonoid supplement).\n* Loratadine (a common anti-allergy medication).\n\nThe core question the study is trying to answer is:\n\n* Is diosmin-hesperidin effective in preventing G-CSF-induced bone pain compared to loratadine?\n* Does the combination of diosmin-hesperidin and loratadine offer better pain prevention than either drug alone?",[29,373,374],"Neutropenia","Bone Pain",[376,377,378,379,380,381,382,383,384,385],"Loratadine","Diosmin","Filgrastim","Granulocyte Colony Stimulating Factor","G-CSF Induced Bone Pain","Hesperidin","Flavonoid","Antihistamine","Prophylaxis","Randomized Controlled Trial","2026-06-23",{"date":388,"type":43},"2026-06-24",{"date":390,"type":43},"2025-03-01",{"date":392,"type":21},"2027-07",{"name":394,"class":110},"Alexandria University",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":403,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":111},"100644736","phase-1-cd45ra-depleted-dli-for-the-prevention-of-viral-infections-in-high-risk-patients-after-haploidentical-transplantation-100644736","NCT07672964","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation","CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study","CD45RADLIPx","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Patients undergoing allogeneic hematopoietic stem cell transplantation (any conditioning regimen or graft source is allowed).\n* Presence of at least one high-risk factor for post-transplant viral infection (any of the following):\n* Age ≥50 years or ≤14 years\n* Non-sibling matched transplantation\n* In vivo or ex vivo T-cell depletion\n* Myeloablative conditioning\n* Conditioning containing radiotherapy\n* Second transplantation\n* CMV IgG or EBV IgG donor\u002Frecipient mismatch (donor positive, recipient negative)\n* History of grade II or higher acute graft-versus-host disease (aGVHD) after transplantation and use of high-dose corticosteroids (prednisone equivalent ≥1 mg\u002Fkg\u002Fday)\n* Availability of a suitable lymphocyte donor (see \"Donor Selection Criteria\").\n* Adequate organ function meeting the following laboratory criteria:\n* Liver function: ALT and AST ≤10× upper limit of normal (ULN); total bilirubin ≤5× ULN\n* Renal function: BUN and creatinine ≤1.25× ULN\n* No cardiac dysfunction on electrocardiogram or echocardiogram\n* Pulmonary function: oxygen saturation \\>90% without supplemental oxygen\n* The patient or legal guardian has the desire and request to receive treatment, signs the informed consent form before treatment, and is willing to comply with the treatment plan, follow-up schedule, and laboratory tests.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n* Active grade II-IV acute graft-versus-host disease (aGVHD)\n* Active aGVHD requiring prednisone or equivalent corticosteroid \\>0.5 mg\u002Fkg\u002Fday\n* Active viral infection\n* Uncontrolled or relapsed malignancy\n* Other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or affect informed consent, study participation, follow-up, or interpretation of results.","14 Years","50 Years",{"count":406,"type":21},30,[24],"The goal of this clinical trial is to learn whether giving patients a special type of donor immune cells (called CD45RA Depleted DLI) can help prevent viral infections after a stem cell transplant. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\nDoes this treatment lower the chance of getting serious viral infections after transplant? What medical problems do patients have when receiving this treatment?",[29,410],"Haplo-identical HCT",[412,413],"CD45RA","DLI","2026-06-22",{"date":353,"type":43},{"date":417,"type":21},"2026-07-01",{"date":419,"type":21},"2028-07-31",{"name":421,"class":110},"Ruijin Hospital",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":111},"100644312","phase-1-cd45ra-depleted-dli-for-the-treatment-of-refractorypersistent-viral-infections-after-haploidentical-transplantation-100644312","NCT07662369","CD45RA-depleted DLI for the Treatment of Refractory\u002FPersistent Viral Infections After Haploidentical Transplantation","Ex Vivo CD45RA-depleted DLI for the Treatment of Refractory\u002FPersistent Viral Infections After Transplantation: a Prospective, Multicenter, Single-arm, Pragmatic Clinical Study","CD45RADLITx","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Patients who have undergone hematopoietic stem cell transplantation.\n* Presence of viremia and\u002For viral infection-related disease caused by a single virus or multiple viruses among the following: CMV, EBV, ADV, BK, B19, JC, HHV-6B, HSV1, or HSV2.\n* Patients who, after ≥2 weeks of first-line therapy, have persistent viral positivity, no relief or worsening of clinical symptoms, or re-infection with the same pathogen after viral clearance.\n* Availability of a suitable lymphocyte donor.\n* Adequate organ function, meeting the following laboratory criteria:\n* Liver function: ALT and AST ≤ 10 × upper limit of normal (ULN), TBIL ≤ 5 × ULN.\n* Renal function: BUN and Cr ≤ 1.25 × ULN.\n* No cardiac insufficiency on electrocardiogram (ECG) or echocardiogram.\n* Pulmonary function: oxygen saturation \\> 90% on room air.\n* Willingness and ability of the patient or their legal guardian to receive treatment, comply with the treatment plan, follow-up schedule, and laboratory examinations, and provision of signed informed consent before any study-specific procedure.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n* Active grade II-IV acute graft-versus-host disease (aGVHD).\n* Prednisone or equivalent corticosteroid dose \\> 0.5 mg\u002Fkg\u002Fday.\n* Receipt of anti-thymocyte globulin (ATG), alemtuzumab (Campath), or other T-cell immunosuppressive monoclonal antibodies within 28 days before enrollment.\n* Less than 28 days after allogeneic transplantation, or receipt of donor lymphocyte infusion (DLI) or virus-specific T cell (VST) therapy within 28 days before enrollment.\n* Uncontrolled or relapsed malignancy.\n* Presence of other serious acute or chronic physical or psychiatric conditions, or laboratory abnormalities, that may compromise patient safety or compliance, or that may interfere with informed consent, study participation, follow-up, or interpretation of study results.",{"count":406,"type":21},[24,124],"The goal of this clinical trial is to learn whether giving patients special donor immune cells (called \"CD45RA Depleted DLI\") can help treat viral infections that have not improved with standard antiviral drugs. These infections occur after a stem cell transplant. The study will also look at the safety of this treatment.",[29,410],[412,413],{"date":386,"type":43},{"date":437,"type":21},"2026-06-01",{"date":439,"type":21},"2028-06-30",{"name":421,"class":110},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":111},"100219481","prospective-cohort-with-hemopathy-in-languedoc-roussillon-100219481","NCT02134574","Prospective Cohort With Hemopathy in Languedoc-Roussillon","Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon","HemoDiag","Inclusion criteria:\n\n* Age over 18\n* Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent\n* Having signed an informed consent\n* Affiliated with a social security scheme\n\nExclusion criteria:\n\n* Minor or major protected\n* Patients who have received treatment for hematological pathology",{"count":450,"type":21},500,"Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.",[29],[454,455,456,457],"Lymphoma,","leukemia,","multiple myeloma,","hodgkin disease","2026-06-17",{"date":414,"type":43},{"date":461,"type":4},"2014-02",{"date":463,"type":21},"2033-06",{"name":465,"class":110},"University Hospital, Montpellier",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":473,"enrollmentInfo":474,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":490},"100560616","prospective-evaluation-of-delayed-effects-of-pediatric-car-t-cell-therapy-100560616","NCT06579469","Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy","Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)","Inclusion Criteria:\n\n* Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+\u002F- 14 days).\n\n  * Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.\n* Age ≤ 30 years at CAR T cell infusion.\n\nExclusion Criteria:\n\n* Active malignancy other than the disease under study.\n* Planned consolidative HSCT within 3 months post CAR T cell infusion.\n* Received or planned additional disease directed therapy post CAR T cell infusion.\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.","30 Years",{"count":475,"type":21},100,"This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and\u002For have damage to the nervous system.",[478,29,319],"B-ALL",[480,481],"CAR T cell infusion","Late Effects","2026-06-16",{"date":484,"type":43},"2026-06-18",{"date":486,"type":43},"2026-01-20",{"date":488,"type":21},"2029-03",{"name":287,"class":110},6,{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":22,"phases":501,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":111},"100603173","phase-4-allergy-delabeling-in-antibiotic-stewardship---intervention-100603173","NCT07133074","Allergy Delabeling in Antibiotic Stewardship - Intervention","Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention","RENEW-IN","Inclusion Criteria:\n\n* all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service\n* reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and\u002For carbapenem)\n\nExclusion Criteria:\n\n* patients with a history of severe cutaneous adverse reaction\n* patients with a history of Stevens-Johnson syndrome\n* patients with a history of toxic epidermal necrolysis\n* patients with a history of drug-induced exfoliative dermatitis\n* patients with a history of drug reaction with eosinophilia and systemic symptoms\n* patients with a history of acute generalized exanthematous pustulosis",{"count":500,"type":21},3800,[502],"PHASE4","The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.",[505,29],"Beta Lactam Allergy",[507,508,509],"penicillin allergy","hematologic cancer","allergy delabeling","2026-06-15",{"date":458,"type":43},{"date":513,"type":43},"2026-04-20",{"date":515,"type":21},"2029-11",{"name":517,"class":110},"Abramson Cancer Center at Penn Medicine",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":524,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":111},"100468784","response-to-influenza-vaccination-in-pediatric-oncology-patients-100468784","NCT05384288","Response to Influenza Vaccination in Pediatric Oncology Patients","Inclusion Criteria:\n\n* Patient ≤ 18 years old at the time of consent receiving care at St. Jude Children's Research Hospital\n* Diagnosed with a hematological malignancy\n* Eligible to receive the current seasonal influenza vaccine\n\nExclusion Criteria:\n\n• Previously received at least one dose of the current seasonal influenza vaccine.",{"count":525,"type":21},150,"Influenza infection occurring during oncologic treatment or following hematopoietic cell transplantation (HCT) is associated with increased risk of morbidity in the form of lower respiratory tract infection (LRTI) and mortality relative to otherwise healthy patients. The study participants have been diagnosed with a hematological malignancy and are eligible to receive the current seasonal influenza (Flu) vaccine.\n\nPrimary Objective\n\n* To determine the feasibility of opening a longitudinal prospective study of IIV immunogenicity in pediatric leukemia patients.\n* To describe the immunogenicity, as measured by the development of cell- and\u002For antibody-mediated influenza specific responses 3 to 5 weeks following vaccination, in a cohort of pediatric leukemia patients.\n\nSecondary Objectives\n\n* To describe whether an immune response, as measured by development of cell- and\u002For antibody-mediated influenza specific responses, is detectable 1-2 weeks following vaccination in a cohort of pediatric leukemia patients.\n* To describe the durability of immunogenicity by measuring cell - and antibody- mediated influenza specific responses at 6 months and 1 year following vaccination in a cohort of pediatric leukemia patients.\n\nExploratory Objectives\n\n* To estimate the clinical effectiveness of influenza vaccine in this cohort by monitoring for the development of clinical diagnosis of influenza in the cohort of enrolled pediatric oncology patients.\n* To correlate results of immune cell frequency in blood, as measured by complete blood count with differential, with development of an immune response to IIV.",[29,528,529],"Pediatric Cancer","Transplant-Related Cancer",[531],"Influenza infection","2026-06-11",{"date":534,"type":43},"2026-06-12",{"date":536,"type":43},"2022-10-07",{"date":538,"type":21},"2029-12-01",{"name":287,"class":110},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":562},"100546929","phase-3-an-extension-study-for-patients-previously-enrolled-in-studies-with-pelabresib-100546929","NCT06401356","An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib","Inclusion Criteria:\n\n1. Eligibility for Ongoing Pelabresib Treatment\n\n   * Able to provide signed informed consent, agreeing to all protocol and ICF requirements.\n   * At least 18 years old and legally able to consent in the study's jurisdiction.\n   * Previously enrolled and currently receiving pelabresib in a parent study.\n   * Demonstrating clinical benefit from pelabresib, as judged by the investigator.\n   * Willing and able to follow all study visits, treatments, and procedures.\n   * Agree to avoid pregnancy or fathering children:\n\n     * Men: Must use highly effective contraception (≥99% effective) and avoid sperm donation from eligibility check through 94 days post-treatment.\n     * Women of childbearing potential (WOCBP): Must test negative for pregnancy at eligibility, use highly effective contraception through 184 days post-treatment, undergo regular pregnancy testing, and avoid breastfeeding and oocyte donation during this period.\n     * Women not of childbearing potential (surgically sterile or postmenopausal ≥12 months without other cause) are eligible.\n\n   Note: Women with amenorrhea due to chemo\u002Fradiotherapy are considered WOCBP and must use contraception.\n2. Eligibility for Survival Follow-up\n\n   * Provide signed informed consent, agreeing to all protocol and ICF requirements.\n   * Are at least 18 years old and legally able to consent.\n   * Were previously enrolled in a pelabresib clinical study.\n   * Are willing and able to comply with follow-up procedures.\n\nExclusion Criteria:\n\n1. Eligibility for Ongoing Pelabresib Treatment\n\n   * Legally institutionalized or under judicial protection.\n   * Enrolled in another interventional clinical trial (excluding the parent study).\n   * History of hypersensitivity to pelabresib, its excipients, or similar drugs.\n   * Significant gastrointestinal issues (e.g., active IBD, unresolved nausea\u002Fvomiting\u002Fdiarrhea \\> Grade 1) that may affect drug absorption.\n   * Any medical condition deemed unsuitable by the investigator.\n   * Uncontrolled illness or condition that may compromise safety or protocol compliance.\n   * Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea\u002Fanagrelide allowed up to 24 hours prior.)\n   * Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.\n   * Used strong CYP3A4 inhibitors\u002Finducers (e.g., St. John's wort) within 2 weeks before first dose. Use during treatment is prohibited.\n   * Female participants who are pregnant, breastfeeding, or not using required contraception.\n   * Male participants who do not agree to use contraception or refrain from sperm donation as specified.\n   * Unwilling or unable to comply with the study protocol.\n2. Eligibility for Survival Follow-up • They are legally institutionalized or under judicial protection.",{"count":548,"type":21},50,[550],"PHASE3","The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and\u002For solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).",[29,319,553],"Advanced Malignancies","2026-06-10",{"date":532,"type":43},{"date":557,"type":43},"2024-08-13",{"date":559,"type":21},"2027-06-30",{"name":561,"class":50},"Novartis Pharmaceuticals",15,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":581,"locationsCount":111},"100636813","phase-1-clinical-study-of-the-safety-and-efficacy-of-allogeneic-tcr-enhanced-v2-t-cell-in-patients-with-malignant-tumors-100636813","NCT07570563","Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.","A Clinical Study on the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell Injection in the Treatment of Patients With Malignant Tumors","Inclusion Criteria:\n\n* Age 18-75 (inclusive).\n* Expected survival time ≥ 3 months.\n* Meets current clinical diagnostic criteria with a confirmed diagnosis of a malignant hematologic tumor or solid tumor, and has failed standard therapy (for solid tumors, at least one evaluable lesion according to RECIST v1.1 is required).\n* Adequate bone marrow reserve and essentially normal liver and kidney function (laboratory tests must meet the following criteria prior to the first allogeneic TCR-enhanced Vδ2 T cell treatment):\n* Hematology: White Blood Cell Count (WBC) ≥ 2.5×10⁹\u002FL, Lymphocyte Count (LY) ≥ 0.8×10⁹\u002FL, Hemoglobin (Hb) ≥ 80 g\u002FL, Platelets (PLT) ≥ 75×10⁹\u002FL.\n* Liver: ALT ≤ 3 × ULN; AST ≤ 3 × ULN; Total Bilirubin ≤ 3.0 × ULN.\n* Kidney: Serum Creatinine ≤ 1.5 × ULN.\n* Cardiac: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as measured by echocardiogram.\n* Pulmonary: Normal oxygen saturation without supplemental oxygen.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1.\n* A negative pregnancy test is required for women of childbearing potential. Both male and female subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.\n* Able to understand the trial requirements and is willing to participate in the clinical study as required.\n* Voluntarily signs the informed consent form for the clinical trial.\n\nExclusion Criteria:\n\n* Known history of allergy, hypersensitivity, intolerance, or contraindication to allogeneic TCR-enhanced Vδ2 T cell or any components of the study drugs (including fludarabine, cyclophosphamide and albumin paclitaxel).\n* Continuous use of immunosuppressants within 1 month prior to allogeneic TCR-enhanced Vδ2 T cell infusion.\n* History of cerebrovascular accident or seizure within 6 months prior to signing the informed consent.\n* Symptomatic brain metastases.\n* Known psychiatric or substance abuse disorders that would compromise compliance with study requirements.\n* Positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) with detectable Hepatitis B virus (HBV) DNA levels outside the normal reference range; positive for Hepatitis C virus (HCV) antibody with detectable HCV RNA; positive for Human Immunodeficiency Virus (HIV) antibody; positive for syphilis.\n* Severe cardiac disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA Class ≥ III), and severe arrhythmia.\n* Active or uncontrolled infection requiring systemic therapy (except for mild urogenital and upper respiratory tract infections).\n* Has not recovered from acute toxic effects of prior therapy (i.e., persisting hematological or organ toxicity ≥ Grade 2 related to prior therapy, excluding abnormalities associated with the study disease and its history).\n* Diagnosed with immunodeficiency.\n* Active infection requiring systemic treatment.\n* Female subjects of childbearing potential planning pregnancy within 2 years after cell infusion; or male subjects whose partners are planning pregnancy within 2 years after cell infusion.\n* Participation in another investigational drug clinical study within 1 month prior to screening.\n* Last anti-tumor therapy administered less than 5 half-lives of the drug prior to planned allogeneic TCR-enhanced Vδ2 T cell infusion.\n* Any other condition deemed by the investigator to make the subject unsuitable for participation in this study.",{"count":571,"type":21},24,[24,124],"The allogeneic TCR-enhanced Vδ2 T cell product is a novel genetically engineered cellular therapeutic. By engineering a specific BTN protein-binding moiety on its cell surface, this product harnesses the intrinsic tumoricidal potential of endogenous Vδ2 T cells and augments BTN protein recognition capability, thereby significantly boosting tumor cell killing potency. Notably, this engineered cell product exhibits no expression of co-stimulatory signaling domains and CD3ζ domains. This design circumvents T cell exhaustion triggered by overactivation and markedly enhances the in vivo persistence of therapeutic cells.\n\nThis is an open, prospective, open-label Phase I\u002FII clinical trial designed to assess the safety and therapeutic efficacy of allogeneic TCR-enhanced Vδ2 T cell injection in patients with relapsed or refractory hematologic malignancies and advanced solid tumors.",[29,319],"2026-06-05",{"date":577,"type":43},"2026-06-08",{"date":575,"type":43},{"date":580,"type":21},"2031-12-31",{"name":582,"class":110},"Chinese PLA General Hospital",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":590,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":593,"conditions":594,"keywords":605,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":142},"100526212","pharmacokinetic-study-of-venetoclax-tablets-crushed-and-dissolved-into-a-solution-100526212","NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution","A Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\n* Age: Patients must be \\\u003C39 years of age at time of study enrollment\n* Diagnosis: Patients may have a diagnosis of any hematologic malignancy\n* Central access: Patients must have an existing venous or arterial access line for PK blood draws\n* Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment\n* Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.\n* Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.\n* Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.","0 Years","38 Years",{"count":406,"type":21},"The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.\n\nPrimary Objectives\n\n• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution\n\nSecondary Objectives\n\n* To evaluate the safety of crushed venetoclax tablets administered as an oral solution\n* To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors\n* To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)\n* To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution",[29,33,190,595,17,596,27,597,255,598,245,246,160,599,600,601,602,603,604],"Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","Chronic Myelogenous Leukemia","Myeloproliferative Neoplasm","Follicular Lymphoma","Burkitt Lymphoma","T-cell Lymphoma","B Cell Lymphoma","Peripheral T Cell Lymphoma","Cutaneous B-Cell Lymphoma",[606,607,608],"Venetoclax","Pediatric AML","Pediatric Relapsed\u002FRefractory AML","2026-06-02",{"date":611,"type":43},"2026-06-04",{"date":613,"type":43},"2023-11-15",{"date":615,"type":21},"2027-12-01",{"name":617,"class":110},"Children's Hospital Medical Center, Cincinnati",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":59,"sex":17,"minAge":4,"maxAge":272,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":626,"conditions":627,"keywords":628,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":111},"100596968","phase-1-tcr-depleted-progenitor-cell-graft-with-early-memory-t-cell-dli-plus-selected-use-of-blinatumomab-in-nave-t-cell-depleted-haploidentical-donor-hematopoietic-cell-transplantation-for-hematologic-malignancies-100596968","NCT07052370","TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","Inclusion Criteria:\n\nRecipient:\n\n* Age less than or equal to 21 years\n* High risk hematologic malignancy whereas allogeneic transplantation is the current standard of care. This includes (but is not limited to):\n\n  * High risk ALL in CR1 or CR2,\n  * any ALL in CR3 or subsequent;\n  * AML in high risk CR1 (AML diagnosis includes myeloid sarcoma),\n  * any AML in CR2 or subsequent,\n  * any therapy related AML;\n  * MDS (primary or secondary),\n  * NK cell, biphenotypic, or undifferentiated leukemia\u002Flymphoma in CR1 or subsequent;\n  * CML in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor, or a history of blast crisis.\n* If prior CNS leukemia, it must be treated and in CNS CR\n* Left ventricular ejection fraction \\> 40%, or shortening fraction ≥ 25%\n* Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml\u002Fmin\u002F1.73m2\n* Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)\n* Bilirubin ≤ 3 times the upper limit of normal for age\n* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n\nDonor:\n\n* At least single haplotype matched (≥ 4 of 8) family member\n* At least 18 years of age\n* HIV negative\n* Regarding donation eligibility, is identified as either:\n\n  * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR\n  * Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271\n\nExclusion Criteria:\n\nRecipient:\n\n* Has a suitable HLA-identical sibling or suitable 12\u002F12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame.\n* Any other active malignancy other than the one for which this HCT is indicated\n* Received a prior allogeneic HCT at any time\n* Received an autologous HCT within the previous 6 months\n* Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment\n* Breast feeding\n* Any current uncontrolled bacterial, fungal or viral infection\n\nDonor:\n\n* Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female\n* If female, breast feeding",{"count":406,"type":21},[24],"This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI.\n\nThe primary objective is:\n\n\\- To assess the safety and feasibility of early CD45RA-depleted DLI administration.\n\nThe secondary objectives are\n\n* To assess the safety and feasibility of the addition of blinatumomab in the early post-transplant period in patients with CD19+ malignancy.\n* To measure and describe the pharmacokinetics of rabbit ATG in HCT recipients on this study.",[29],[629],"Hematopoietic Cell Transplant",{"date":609,"type":43},{"date":632,"type":43},"2025-09-25",{"date":634,"type":21},"2030-12",{"name":287,"class":110},{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":17,"minAge":643,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":22,"phases":645,"briefSummary":646,"conditions":647,"keywords":652,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":111},"100569096","lets-get-real-family-health-communication-tool-in-pediatric-stem-cell-transplant-and-cellular-therapy-100569096","NCT06689800","Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Let's Get REAL: A Pilot Trial of a Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Inclusion Criteria Youth:\n\n* Children or adolescents 8-17 years of age referred for SCTCT.\n* Diagnosis of malignant or nonmalignant disorder.\n* Referred for any type of SCTCT. Autologous and allogeneic stem cell and cellular therapies are eligible.\n* Planning to meet with a provider to discuss SCTCT.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed assent document.\n* Must speak English and be cognitively able to participate.\n\nInclusion Criteria Parents:\n\n* Parent or guardian of a child 8-17 years of age with any diagnosis referred for any type of SCTCT. Diagnoses may include malignant and nonmalignant disorders. Autologous and allogeneic stem cell and cellular therapies are eligible. Parent or guardian is defined as an adult who usually cares for the youth and has authority to make medical decisions for them.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed consent document.\n* Must speak English and be cognitively able to participate.\n\nExclusion Criteria Youth:\n\n* Active medical problems severe enough to preclude study participation at the time of recruitment.\n\n  * Patients who are otherwise eligible, but whose primary transplant physician does not want them to participate in the study.\n* Lacks cognitive capacity to complete study activities, as determined by consenting professional.\n\nExclusion Criteria Parents:\n\n* Their youth referred for SCTCT does not assent to participate.","8 Years",{"count":295,"type":21},[185],"The investigators will conduct a pilot feasibility and efficacy trial of a newly developed family health communication tool (called Let's Get REAL) in increasing youth involvement in real-time stem cell transplant and cellular therapy decisions (SCTCT). The investigators will pilot the intervention among 24 youth and their parents, stratified by youth age (stratum 1, 8-12 years of age and stratum 2, 13-17 years of age).",[29,319,648,649,650,651],"Sickle Cell Disease","Aplastic Anemia","Immune Deficiency","Metabolic Disorder",[653,654,655,656,657],"Pediatric","Family","Decision making","Health Communication","Intervention",{"date":611,"type":43},{"date":660,"type":43},"2024-11-26",{"date":662,"type":21},"2026-11-30",{"name":664,"class":110},"Washington University School of Medicine",{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":671,"enrollmentInfo":672,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":673,"conditions":674,"keywords":675,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":111},"100581893","natural-history-study-to-determine-drug-metabolism-phenotype-and-appropriate-germline-source-dna-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplant-100581893","NCT06856226","Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant","* INCLUSION CRITERIA:\n* Age \\>=18 years\n* Participants must be enrolled on a clinical trial at the NIH Clinical Center (CC) under which they will donate or receive an allogeneic HSCT. The participant and their donor must enroll together to provide a complete set of samples for analysis.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Donors are not allowed to enroll without a recipient\n* Prior allogeneic HSCT\n* History of psychiatric disorder which may compromise compliance with protocol requirements.\n* Pregnant and lactating individuals","120 Years",{"count":369,"type":21},"Background:\n\nAfter an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.\n\nPost-HSCT recipients may receive a medication in which the dosing needs to be adjusted based on genetic variation.\n\nWhile genes in donor genome may influence dosing and administration of some agents, the majority of established gene-drug pairs in pharmacogenetics are related to expression of metabolic or transporting enzymes located in recipients tissues, often the liver.\n\nDetermining which genetic variants influence drug disposition in HSCT recipients is complicated by chimerism in samples that are routinely collected for determining genotype. However, chimerism in tissues is poorly studied in this patient population.\n\nObjectives:\n\nTo determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic HSCT.\n\nEligibility:\n\nPeople ages 18 years and older who are enrolled on a clinical trial at the NIH Clinical Center under which they will donate or receive an allogeneic HSCT.\n\nDesign:\n\nDNA is collected prior to HSCT and for two years after HSCT.\n\nBlood will be collected and skin fibroblast cell lines will be established prior to HSCT to serve as a reference genome.\n\nBlood, buccal cells, skin, and hair will be monitored for the development of mixed chimerism via detection of short tandem repeats. Liver biopsies will be collected from participants undergoing hepatic surgery.\n\nPharmacoscan arrays will be conducted to determine which samples are useful for pharmacogenetic testing in participants who receive allogeneic HSCT.\n\nA probe drug cocktail will be administered pre- and post-HSCT to determine if transplantation alters the metabolic phenotype of liver enzymes.\n\n...",[33,190,29],[676,629,189,677,678],"Allogeneic Transplant","peripheral blood transplant","Chimerism","2026-05-23",{"date":681,"type":43},"2026-05-27",{"date":683,"type":43},"2026-03-04",{"date":685,"type":21},"2028-12-01",{"name":687,"class":688},"National Cancer Institute (NCI)","NIH",{"id":690,"slug":691,"hasResults":12,"nctId":692,"briefTitle":693,"officialTitle":694,"acronym":695,"eligibilityCriteria":696,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":697,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":699,"conditions":700,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":702,"lastUpdatePostDateStruct":703,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":710},"100640357","identifying-cellular-and-molecular-determinants-of-efficacy-and-resistance-in-patients-undergoing-car-t-therapy-100640357","NCT07609485","Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy","Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy at the CHU, Lille: Biological Prospective Collection and Storage","CAR-Lille","Inclusion Criteria:\n\n* Male or female aged ≥ 18 years and able to provide informed consent\n* Any indication,\n* Commercially available CART therapies,\n* Any conditioning.\n\nExclusion Criteria:\n\n* Freedom privacy\n* Absence of medical coverage\n* Patients receiving CART or CAR-based cellular therapies which are not commercially available.",{"count":698,"type":21},700,"In recent years we have witnessed a breakthrough in the treatment of leukemia and lymphoma using autologous CAR-T cells that can induce durable remission in patients. Multiple approved CAR-T therapy trials, including those at our centre, have consistently yielded objective tumor regression rates in about 40% of patients that have progressed after multiple previous chemo or targeted therapies. However, not all the patients respond to the therapy and rate of relapse is unfortunately common. Hence, the identification of biomarkers to track clinical activity of CAR-T and as predictive tools for patient selection is critical in our quest to develop personalized cellular therapies, where both degree and duration of response varies among different patients. For CAR-T therapy to truly live up to its promise, it is imperative to increase durable response rates. The success of CAR-T therapy not only depends in targeting antigens (e.x. CD19, BCMA) commonly expressed by malignant cells but also limited by poor persistence and trafficking of infused CAR-T cells in vivo. Hence highlighting the need to identify factors that exhibit optimal homing to the target sites and are able to persist long-term for continuous tumor surveillance. Furthermore, we lack comprehensive knowledge on how certain patients with leukemia and lymphoma achieve complete durable anti-cancer response upon CAR-T infusion whereas other either partially respond to the therapy and then relapse, or do not respond at all. Determining cellular and molecular factors that contribute to optimal homing of CAR-T cell to target sites as well as their long-term persistence will help us to design improved CAR-T based therapy against lymphoma other malignancies.",[701,29],"Cancer","2026-05-19",{"date":681,"type":43},{"date":705,"type":43},"2021-02-18",{"date":707,"type":21},"2028-02-18",{"name":709,"class":110},"University Hospital, Lille",2]